Additionally, the tumor regression observed with the combination of trastuzumab and CSF1R inhibition suggests that simultaneously targeting cancer cells and modulating the myeloid compartment may enhance macrophage-mediated cytotoxicity. Here, CSF1R is linked to cancer.